1. Home
  2. CANF vs ZBAI Comparison

CANF vs ZBAI Comparison

Compare CANF & ZBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CANF
  • ZBAI
  • Stock Information
  • Founded
  • CANF 1994
  • ZBAI 2015
  • Country
  • CANF Israel
  • ZBAI United States
  • Employees
  • CANF N/A
  • ZBAI N/A
  • Industry
  • CANF Biotechnology: Pharmaceutical Preparations
  • ZBAI Professional Services
  • Sector
  • CANF Health Care
  • ZBAI Consumer Discretionary
  • Exchange
  • CANF Nasdaq
  • ZBAI Nasdaq
  • Market Cap
  • CANF 7.9M
  • ZBAI 17.3M
  • IPO Year
  • CANF N/A
  • ZBAI N/A
  • Fundamental
  • Price
  • CANF $1.12
  • ZBAI $0.93
  • Analyst Decision
  • CANF Strong Buy
  • ZBAI
  • Analyst Count
  • CANF 2
  • ZBAI 0
  • Target Price
  • CANF $14.00
  • ZBAI N/A
  • AVG Volume (30 Days)
  • CANF 444.9K
  • ZBAI 135.9K
  • Earning Date
  • CANF 05-20-2025
  • ZBAI 03-13-2025
  • Dividend Yield
  • CANF N/A
  • ZBAI N/A
  • EPS Growth
  • CANF N/A
  • ZBAI N/A
  • EPS
  • CANF N/A
  • ZBAI N/A
  • Revenue
  • CANF $674,000.00
  • ZBAI $670,000.00
  • Revenue This Year
  • CANF $461.72
  • ZBAI N/A
  • Revenue Next Year
  • CANF N/A
  • ZBAI N/A
  • P/E Ratio
  • CANF N/A
  • ZBAI N/A
  • Revenue Growth
  • CANF N/A
  • ZBAI 67.50
  • 52 Week Low
  • CANF $1.02
  • ZBAI $0.58
  • 52 Week High
  • CANF $4.69
  • ZBAI $2.50
  • Technical
  • Relative Strength Index (RSI)
  • CANF 40.25
  • ZBAI N/A
  • Support Level
  • CANF $1.02
  • ZBAI N/A
  • Resistance Level
  • CANF $1.20
  • ZBAI N/A
  • Average True Range (ATR)
  • CANF 0.06
  • ZBAI 0.00
  • MACD
  • CANF 0.01
  • ZBAI 0.00
  • Stochastic Oscillator
  • CANF 41.30
  • ZBAI 0.00

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

About ZBAI ATIF Holdings Limited Ordinary Shares

ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.

Share on Social Networks: